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Blockade of Angiotensin II type-1 receptor reduces
oxidative stress in adipose tissue and ameliorates
adipocytokine dysregulation
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Dysregulated production of adipocytokines may be involved
in the development of atherosclerotic cardiovascular disease
in metabolic syndrome and chronic kidney disease (CKD)
associated with metabolic syndrome. The aim of this study
was to determine the effects of treatment with angiotensin II
(Ang II) type-1 receptor blocker (ARB) on the regulation of
adipocytokines. Olmesartan, an ARB, significantly blunted the
age- and body weight-associated falls in plasma adiponectin
both in genetically and diet-induced obese mice, without
affecting body weight, but had no effect on plasma
adiponectin levels in lean mice. Olmesartan also ameliorated
dysregulation of adipocytokines in obesity, such as tumor
necrosis factor-a, plasminogen activator inhibitor-1,
monocyte chemotactic protein-1, and serum amyloid A3.
Olmesartan significantly reduced reactive oxygen species
originating from accumulated fat and attenuated the
expression of nicotinamide adenine dinucleotide phospho
hydrogenase oxidase subunits in adipose tissue. In cultured
adipocytes, olmesartan acted as an antioxidant and improved
adipocytokine dysregulation. Our results indicate that
blockade of Ang II receptor ameliorates adipocytokine
dysregulation and that such action is mediated, at least in
part, by targeting oxidative stress in obese adipose tissue.
Ang II signaling and subsequent oxidative stress in adipose
tissue may be potential targets for the prevention of
atherosclerotic cardiovascular disease in metabolic syndrome
and also in metabolic syndrome-based CKD.
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The metabolic syndrome is a cluster of insulin resistance,
hypertension, dyslipidemia, and visceral obesity.1 Recent
studies demonstrated that the metabolic syndrome is also
strongly associated with chronic kidney disease (CKD).2,3 In
addition to the effects of elevated blood pressure and blood
glucose, there is evidence to suggest that visceral obesity per
se can cause vascular endothelial dysfunction resulting in
renal damage (termed obesity-related glomerulopathy).4,5
Cardiovascular diseases are major causes of mortality and
morbidity in the metabolic syndrome and also in CKD.6
Several biomarkers such as microalbuminuria and plasma
homocysteine, and C-reactive protein levels, have been
investigated as potential risk factors for cardiovascular disease
in CKD.7–12 Adipose tissue was previously considered as an
energy-storage organ, but recent research has demonstrated
that this tissue produces and secretes a variety of biologically
active molecules, conceptualized as adipocytokines.13–18
Increased production of plasminogen activator inhibitor-1
(PAI-1) from accumulated visceral fat leads to thrombotic
tendency, and high levels of plasma tumor necrosis factor-a
(TNF-a) result in inflammation.15,16,19 Adiponectin, which is
an adipose-specific endocrine factor, exhibits anti-athero-
genic, anti-diabetic, and anti-inflammatory properties,20–23
but its plasma level is low in visceral obesity.18 Hypoadipo-
nectinemia is associated with coronary artery disease, type 2
diabetes, essential hypertension, and metabolic syn-
drome.24–28 Interestingly, it was demonstrated that plasma
adiponectin level could be a negative predictor of cardiovas-
cular outcomes among patients with end-stage renal
disease.29,30 Considered together, dysregulation of adipo-
cytokine may be also involved in the development of
cardiovascular diseases in CKD associated with metabolic
syndrome.
Regimens designed to increase plasma adiponectin levels
and to ameliorate adipocytokine dysregulation might prevent
the development of cardiovascular diseases. The renin–
angiotensin system (RAS), a hormonal cascade that includes
angiotensinogen, renin, angiotensin-converting enzyme
(ACE), angiotensin (Ang), and its receptors, is involved in
the maintenance of systemic blood pressure. In pathological
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state, Ang II also functions as a local biologically active
mediator in the progression of cardiovascular remodeling
and nephropathy through Ang II type-1 (AT1) receptor.31,32
Excessive production of local Ang II in the kidney increases
intraglomerular pressure resulting in microalbuminuria, and
enhances synthesis of extracellular matrix.32 Therefore, AT1
receptor blockers (ARBs) are considered to have cardio- and
reno-protective effects beyond their anti-hypertensive ef-
fects.33–35 Moreover, several reports demonstrated that ARBs
reduced the risk of new-onset diabetes in humans.36 Recently,
RAS blockers were reported to increase plasma adiponectin
concentrations in patients with essential hypertension.37
However, the effect of ARB on adipose-function, that is, adipo-
cytokine production, has not been defined in experimental
study. In the present study, we investigated the effects of
olmesartan, an ARB, on the dysregulation of adipocytokines,
with a special focus on adiponectin.
RESULTS
Effects of olmesartan on plasma adiponectin levels
We treated lean C57BL/6J and obese KKAy mice with
olmesartan and investigated the changes in plasma adipo-
nectin levels. We analyzed KKAy mice as an obese mouse
model because KKAy mice exhibit phenotypes of the
metabolic syndrome including obesity, diabetes, dyslipide-
mia, fatty liver, hypertension and hypoadiponectinemia.38
Plasma adiponectin concentrations were similar in 8- and 20-
week-old C57BL/6J mice (34.371.4 and 38.171.2 mg/ml,
respectively). In contrast, plasma adiponectin concentrations
in obese KKAy mice decreased with age, in parallel with the
increase in body weight (8-week-old: 25.271.3, 20-week-old:
16.570.9 mg/ml). Lean C57BL/6J and obese KKAy mice
(21-week-old) were treated with olmesartan for 2 weeks.
Olmesartan treatment resulted in a significant fall in blood
pressure level but did not affect the body weights of both
C57BL/6J and KKAy mice, compared with control mice
(Table 1). Olmesartan significantly prevented the decline in
plasma adiponectin in obese KKAy mice (Figure 1a, Table 1).
In contrast, olmesartan treatment did not significantly
change plasma adiponectin concentrations in lean C57BL/
6J mice (Figure 1b, Table 1). To confirm the effect of
olmesartan in preventing the reduction in plasma adipo-
nectin concentrations during the development of obesity,
we repeated the experiments in genetically obese db/db and
diet-induced obesity (DIO) mice, and investigated the
changes in plasma adiponectin concentrations. Olmesartan
treatment blunted the reduction of plasma adiponectin both
in db/db and diet-induced obesity mice (Figure 1c and d).
Furthermore, adiponectin messenger RNA (mRNA) levels in
adipose tissue were significantly higher in olmesartan-treated
mice compared with control KKAy mice (Figure 1e). Insulin
tolerance tests showed improved insulin sensitivity in
olmesartan-treated KKAy mice (Figure 1f), compared with
control KKAy mice.
Effects of olmesartan on adipocytokine expression
To test whether olmesartan directly affects the adipose tissue
to improve the obesity-related low plasma adiponectin level,
we investigated the expression of AT1a receptor mRNA in
various tissues of mice. The expression level of AT1a receptor
in adipose tissue was abundant, compared with heart, kidney,
and skeletal muscle, which are considered as the major target
organs of ARB,39,40 but there was no significant difference in
AT1a receptor mRNA levels of adipose tissues between lean
C57BL/6J and obese KKAy mice (Figure 2a). These results
suggest that the adipose tissue is one of the major target
organs of ARB in vivo. We also investigated the effect of ARB
on the dysregulated expressions of other adipocytokines. The
mRNA expression levels of TNF-a, PAI-1, monocyte
chemotactic protein-1 (MCP-1), and serum amyloid A3
(SAA3), which is an acute phase reactant in adipose tissue
like C-reactive protein,41,42 were overexpressed in the obese
Table 1 | Body weight, SBP, plasma glucose, insulin, and plasma adiponectin concentrations in C57BL/6 and KKAy mice before
and after 2-week treatment with olmesartan
Control (n=4) Olmesartan (n=4)
Before After Before After
C57BL/6 mice
Body weight (g) 22.070.7 24.271.3z 22.570.4 24.570.3z
SBP (mmHg) 100.372.9 105.571.3 106.773.0 86.074.1y,*
Glucose (mmol/l) 10.370.5 10.870.2 9.970.5 10.571.2
Insulin (nmol/l) 0.0670.01 0.0570.01 0.0770.01 0.0570.01
Adiponectin (mg/ml ) 37.772.6 38.073.3 38.871.0 37.872.9
KKAy mice
Body weight (g) 51.271.8 51.071.6 50.971.1 51.770.8
SBP (mmHg) 116.473.3 119.873.9 110.972.4 80.072.9y,*
Glucose (mmol/l) 26.372.7 27.472.8 26.672.2 24.173.0
Insulin (nmol/l) 13.970.7 17.671.0z 13.071.1 14.672.3
Adiponectin (mg/ml) 15.671.1 12.670.4 z 15.171.7 18.171.6*
SBP, systolic blood pressure.
Values are mean7s.e.m. *Po0.01, compared with control mice.
zPo0.05, yPo0.01, compared with the basal value (before olmesartan treatment).
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KKAy mice compared with lean C57BL/6J mice. Figure 2b
clearly shows that treatment with olmesartan attenuated the
enhanced mRNA expressions of TNF-a, PAI-1, SAA3, and
MCP-1 in obese KKAy mice, but not in lean C57BL/6J
mice. These findings indicate that olmesartan does not
affect the expression of adipocytokines in the lean mouse,
but improves the dysregulation of adipocytokines in the
obese mouse. In the next step, we examined the molecular
mechanism of the action of ARB on adipocytokines in
obese mice.
Effect of olmesartan on reactive oxygen species in adipose
tissue
It has been reported that ARBs improve oxidative stress in
blood vessels and skeletal muscles.40,43 Recently, Furukawa
et al.38 reported that reactive oxygen species (ROS) are
increased in obesity before the rise in plasma glucose
concentrations. They demonstrated that actively produced
ROS originated from accumulated fat, which subsequently
caused dysregulation of various adipocytokines, such as
adiponectin, PAI-1, and TNF-a. ARBs might ameliorate
adipocytokine dysregulation through a reduction of oxidative
stress in adipose tissue. To test this hypothesis, we measured
the concentration of adipose thiobarbituric acid reactive
substance (TBARS), a marker of lipid peroxidation (LPO), in
C57BL/6J and KKAy mice. Adipose TBARS concentrations
were higher in KKAy mice than in C57BL/6J mice, in
agreement with previous data.38 Treatment with olmesartan
markedly attenuated adipose TBARS concentrations in obese
KKAy mice, but no such effect was observed in lean C57BL/6J
mice (Figure 3a). Moreover, plasma levels of H2O2, a
hazardous ROS against tissues and cells, were also attenuated
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Figure 1 | Effects of olmesartan on plasma concentrations of
adiponectin in mice. (a and b) Twenty-one-week-old KKAy
and C57BL/6J mice were treated with olmesartan (Olme), or no
drug (Control) for 2 weeks (n¼ 4, each). Plasma adiponectin
concentrations were measured once a week. (c) Sixteen-week-old
db/db mice were treated with olmesartan (Olme), or no drug
(Control) (n¼ 9, each) for 2 weeks. (d) Eight-week-old C57BL/6J
mice were fed high fat/high sucrose. At 21 weeks of age, they
were fed the same diet mixed with either olmesartan (Olme) or no
drug (Control) (n¼ 5, each) for 3 weeks. Plasma adiponectin
concentrations were presented as percentage change relative to
their levels before olmesartan treatment. (e) Adiponectin mRNA
expression in adipose tissues. The values were normalized to the
level of cyclophilin mRNA. (f) Insulin sensitivity of olmesartan-treated
KKAy mice. Glucose curves under the insulin tolerance test. Plasma
glucose levels were normalized to those at 0 min (100%). In sections
a–d and f, open circles: control group, solid circles: olmesartan group.
Values are mean7s.e.m., *Po0.05 compared with control mice.
Similar results were obtained in another independent experiment.
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Figure 2 | Effects of olmesartan on mRNA expression of adipo-
cytokines in mice. (a) Expression levels of AT1a receptor mRNA in
various mouse tissues. Values are normalized to the level of 36B4
mRNA. (b) The mRNA expression levels of TNF-a, PAI-1, SAA3, and
MCP-1 in adipose tissue of C57BL/6J and KKAy mice treated with
olmesartan (Olme), or no drug (Cont) (n¼ 4, each). The values were
normalized to the level of cyclophilin mRNA. Data displayed in A and
B are expressed as mean7s.e.m. *Po0.05, **Po0.01.
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by olmesartan treatment in obese KKAy mice but not in lean
C57BL/6J mice (Figure 3b).
Effects of olmesartan on production and removal system of
fat ROS
Next, we investigated the expression of genes related to the
production and removal of ROS in adipose tissue and the
effects of olmesartan on their expression levels. Nicotinamide
adenine dinucleotide phospho hydrogenase (NADPH) oxi-
dase complex is a major source of ROS in various organs
especially in accumulated fat.38,44 The NADPH oxidase
complex consists of membrane-associated flavocytochrome
b558 family of proteins, which includes gp91
phox and p22phox
as well as cytosolic components p47phox p67phox, and p40phox
The expression levels of all subunits were markedly
augmented in adipose tissue of obese KKAy mice (Figure 4),
as described previously.38 In obese KKAy mice, we also found
increased expression of transcriptional factor PU.1, which is
known to upregulate the transcription of NADPH oxidase
subunits.45 Olmesartan clearly reduced the expression
of NADPH oxidase subunits and PU.1 in the adipose tissue
of obese KKAy mice, but had no effect on the expression of
these genes in lean C57BL/6 mice. The expression levels
of CU, Zn-superoxide dismutases, and catalase, the ROS
elimination system, were decreased in obese KKAy mice, but
olmesartan did not affect the expression of these genes.
Effects of olmesartan on adipocytokines in adipocytes
In the above experiments, we demonstrated that ARB
reduced ROS production in obese adipose tissue. Recently,
RAS inhibitors were reported to prevent oxidative stress-
induced apoptosis of vascular endothelial cells.46 Therefore,
to investigate whether ARB directly affects downstream ROS-
mediated adipocytokine dysregulation, we conducted in vitro
experiments using primary adipocytes. We used differen-
tiated adipocytes derived from stromal vascular cells (SVCs)
of mouse adipose tissues. The secretion of adiponectin from
adipocytes was diminished by incubation with H2O2 in a
dose-dependent manner (Figure 5a). Antioxidant N-acetyl
cysteine canceled the H2O2-induced inhibition of adiponec-
tin secretion, as described previously.38 These results
validated the experimental procedure and H2O2 treatment
in this study. In subsequent experiments, olmesartan resulted
in a significant amelioration in the inhibitory effect of H2O2
on adiponectin secretion, whereas it had no effect on basal
adiponectin secretion (Figure 5b). ACE inhibitor, captpril,
significantly but slightly ameliorated oxidative stress-induced
impairment of adiponectin production (Figure 5c). The
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Figure 3 | (a) Effects of olmesartan on LPO levels in adipose
tissues of C57BL/6J and KKAy mice treated for 2 weeks with
olmesartan (Olme), or no drug (Cont) (n¼ 4, each). The level of
LPO in adipose tissue homogenates was measured as TBARS. (b)
Effects of olmesartan on plasma H2O2 concentrations in mice. Data
are mean7s.e.m. *Po0.05, **Po0.01. MDA, malondialdehyde.
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Figure 4 | Effects of olmesartan on mRNA expression levels of
NADPH oxidase subunits, PU.1, Cu, Zn-superoxide dismutases
and catalase in adipose tissues of C57BL/6J and KKAy mice
treated for 2 weeks with olmesartan (Olme), or no drug (Cont)
(n¼ 4, each). Values are normalized to the level of cyclophilin mRNA
and are expressed as mean7s.e.m. *Po0.05, **Po0.01.
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effect of olmesartan on adiponectin production was observed
at mRNA expression level (Figure 5d). The mRNA expression
levels of PAI-1 and MCP-1 were elevated in H2O2-treated
adipocytes. Treatment with olmesartan suppressed the
elevation of mRNA expressions of PAI-1 and MCP-1 in
H2O2-treated adipocytes but not in untreated adipocytes.
These results suggest that amelioration of adipocytokine
dysregulation by ARB is mediated, at least in part, via its anti-
oxidative effect, in addition to reduction of ROS production.
DISCUSSION
In the present study, we demonstrated for the first time
that blockade of AT1 receptor ameliorates adipocytokine
dysregulation including hypoadiponectinemia using various
obese mouse models. Furthermore, ARB ameliorated
adipocytokine dysregulation in an obesity-specific manner.
We also demonstrated that such action is mediated, at least in
part, by targeting oxidative stress in obese adipose tissue.
We found that the ARB, olmesartan, prevented the
obesity-related decline in plasma adiponectin concentration.
Olmesartan also suppressed the expression of other adipo-
cytokines such as TNF-a, PAI-1, SAA3, and MCP-1, which
were upregulated in obesity. These results suggest that
olmesartan can improve adipocytokine dysregulation in an
obesity-specific manner. Recently, it was reported that
activation of RAS by Ang II infusion elicited hypoadipo-
nectinemia.47 What is (are) the mechanism(s) by which ARB
improve adipocytokine dysregulation in adipose tissue?
Several studies showed that Ang II promotes and ARBs
prevent ROS generation by modulation of NADPH oxidase
in atherosclerotic blood vessels and diabetic kidney.43,48–50 In
the present study, we demonstrated that ARB ameliorated
TBARS in obese adipose tissues, a marker of LPO, and
attenuated the expression levels of all subunits of NADPH
oxidase and their upstream transcriptional factor, PU.1,
which was upregulated in the obese adipose tissue (Figure 3b
and ref.38). Inhibition of ROS generation via NADPH oxidase
in adipose tissue may be one of the mechanisms to ameliorate
of adipocytokine dysregulation by ARB.
We also investigated whether ARB directly affects down-
stream ROS-mediated adipocytokine dysregulation using
cultured adipocytes. The results showed that ARB amelio-
rated H2O2-mediated adipocytokine dysregulation (Figure 5).
It was reported that oxidative stress modulates RAS in
vascular endothelial cells.51 Recently, Akishita et al.46 demon-
strated that RAS inhibitors, including olmesartan, inhibited
H2O2-induced apoptosis of endothelial cells. Captopril, an
ACE inhibitor, slightly but significantly ameliorated the
inhibitory effect of H2O2 on adiponectin secretion (Figure
5c), suggesting that RAS inhibition at the level of ACE may
ameliorate ROS-mediated impairment of adiponectin secre-
tion. However, captopril had much less effective than ARB,
also suggesting that direct antioxidant property of this ARB
besides AT1 receptor blockade and/or activation of AT2
under the presence of an ARB showed inhibition against the
ROS cascade. In our in vitro experiments, sarile ([Sar1, Ile8]
angiotensin II), a peptide Ang II receptor antagonist did not
show significant effects (data not shown). This data might
support the above interpretation. Therefore, the entire
molecular mechanism(s) of oxidative stress-related activation
of RAS remains unclear. Considered together, amelioration of
adipocytokine dysregulation in obesity by ARB is mediated,
at least in part, by its anti-oxidative effect, in addition to
reduction of ROS production.
Peroxisome proliferator-activated receptor (PPAR)-g-ago-
nists, thiazolidinediones, were reported to improve adipo-
cytokine dysregulation including adiponectin.52,53 In vitro
studies demonstrated that some ARBs, such as telmisartan
and irbesartan, had PPAR-g agonistic effect and enhanced the
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Figure 5 | Effects of olmesartan on production of adipocytokines
in adipocytes. (a) The secretion of adiponectin from adipocytes
exposed to ROS, with or without antioxidant N-acetyl cysteine.
Differentiated adipocytes derived from SVCs (day 7) were exposed to
the indicated concentrations of H2O2 and N-acetyl cysteine (n¼ 3,
each). (b) Effects of olmesartan on adiponectin secretion by
adipocytes exposed to ROS. Differentiated adipocytes were treated
with the indicated concentrations of H2O2 and olmesartan (Olme)
(n¼ 3, each). Adiponectin secretion in media was analyzed by
adiponectin enzyme-linked immunosorbent assay. The values of
vehicle-treated adipocytes were arbitrarily set as 1.0. Values are
expressed mean7s.e.m. *Po0.05, **Po0.01. Similar results were
obtained in three other independent experiments. (c) Effects of
captopril on adiponectin secretion by adipocytes exposed to ROS.
Differentiated adipocytes were treated with the indicated concen-
trations of H2O2 and captpril (Capt) (n¼ 3, each). Similar results were
obtained in two other independent experiments. (d) Effects of
olmesartan on mRNA expressions of various adipocytokines. Values
are expressed as mean7s.e.m. after normalization to the level of
cyclophilin mRNA. *Po0.05, **Po0.01.
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production of adiponectin in 3T3-L1 adipocytes.54–56 Olme-
sartan might ameliorate adipocytokine dysregulation
through PPAR-g activation. However, this is unlikely because
it was reported that olmesartan did not have PPAR-g
agonistic effect in vitro.54 In our present in vivo and in vitro
studies, we could not observe significant changes in mRNA
expression levels of PPAR-g target genes, such as aP2 and
CD36, following olmesartan treatment (data not shown). It is
also possible that amelioration of adipocytokine dysregula-
tion involves other pathways downstream of ROS such as
mitogen-activated protein kinase, and janus kinase-signal
transducer, and activator of transcription pathways.57,58 The
effect of AT1 blocker may not be entirely owing to the
blockade of AT1. When AT1 is blocked, increase Ang II may
act on AT2 receptor. AT2 stimulation by ARB is reported to
result in renal production of nitric oxide.59 It should be also
considered that nitric oxide production via AT2 stimulation
by ARB may improve adypocytokine dysregulation. Further
studies are needed to elucidate the entire mechanism(s) by
which ARB improves adipocytokine dysregulation in adipose
tissue.
The present study clearly demonstrated that blockade of
AT1 receptor ameliorated adipocytokine dysregulation in
adipose tissue of obesity. It should be clinically relevant that
ARB, which is widely used for the treatment of hypertension,
ameliorate adipocytokine dysregulation in obesity, and
metabolic syndrome. These results suggest that Ang II
signaling and subsequent oxidative stress in adipose tissue
may be potential targets for the prevention of atherosclerotic
cardiovascular disease in metabolic syndrome and also in
metabolic syndrome-based CKD.
MATERIALS AND METHODS
Animals and experimental protocol
All animals were obtained from Clea Japan (Tokyo, Japan). In
C57BL/6J and KKAy mice studies, 21-week-old female mice were
treated with or without olmesartan for 2 weeks (n¼ 4, each). Mice
of the olmesartan group were fed regular chow containing 0.0015%
olmesartan medoxomil (kindly provided by Sankyo Co., Tokyo,
Japan). We selected the dose of the drug in this study so that it
produces a sufficient fall in blood pressure without affecting food
intake or body weight. In db/db mice studies, 16-week-old female
db/db mice were treated with or without olmesartan (0.003%
olmesartan medoxomil) for 2 weeks (n¼ 9 per group). In diet-
induced obesity mice studies, 8-week-old female C57BL/6J mice
were fed high-fat/high-sucrose (HF/HS) diet (Oriental Yeast). At the
age of 21 weeks, the mice were treated with or without olmesartan
(0.003% olmesartan medoxomil) for 3 weeks (n¼ 5 per group).
Subcutaneous adipose tissues (inguinal region) were analyzed in
these studies. All experimental protocols described in this report
were approved by the Ethics Review Committee for Animal
Experimentation of Osaka University.
Blood analysis
All blood samples were collected after 6-h fast. Plasma concentra-
tions of adiponectin, glucose, insulin, and H2O2 were measured by
the adiponectin enzyme-linked immunosorbent assay kit (Otsuka,
Tokushima, Japan), the glucose CII-test (Wako Pure Chemical,
Osaka, Japan), the insulin measurement enzyme-linked immuno-
sorbent assay kit (Morinaga, Yokohama, Japan), and the Amplex
Red hydrogen peroxide assay kit (Molecular Probe Inc., Leiden, The
Netherlands), respectively.
Isolation, culture, and differentiation of SVCs
Subcutaneous adipose tissues (inguinal region) were removed from
8-week-old C57BL/6J mice, and SVCs were obtained by using a
collagenase digestion procedure.60 Adipose tissues were incubated
with digestion medium (Dulbecco’s modified Eagle’s medium
containing 1 mg/ml type II collagenase (Sigma-Aldrich Co., St
Louis, MO, USA, No. C6885)) for 60 min in a shaking water bath at
371C. After filtration and centrifugation, the pellet SVCs were seeded
in 12-well plates, and cultured until confluence in the culture
medium (Dulbecco’s modified Eagle’s medium containing 10% fetal
bovine serum and 200 mM ascorbic acid). Two days after confluence
(day 0), the medium was switched to differentiation medium
(culture medium plus 5 mM troglitazone (kindly provided by Sankyo
Co.), 0.25 nM dexamethasone, 0.5 mM 3-isobutyl-1-metyl-xanthin,
and 10 mg/ml insulin). Two days later, the differentiation
medium was switched to maintenance medium (culture medium
plus 10 mg/ml insulin). At day 7, the SVCs were differentiated into
adipocytes.
Effect of olmesartan on ROS and adipocytokine production in
adipocytes
Differentiated adipocytes derived from SVCs (day 7) were incubated
with serum-free culture medium containing the indicated reagents
or vehicle for 12 h. The medium was replaced with freshly prepared
medium containing the same reagents, and further incubated for
12 h. Then, the medium was collected to measure adiponectin
secretion using the aforementioned adiponectin enzyme-linked
immunosorbent assay kit, and the cells were harvested for RNA
analysis. Because olmesartan medoxomil is a prodrug, we performed
in vitro experiments using RNH-6270, which is the active form of
olmesartan medoxomil (kindly provided by Sankyo Co.). Captopril,
an ACE inhibitor, was kindly provided by Sankyo Co.
Blood pressure measurement
Systolic blood pressure was measured with an automatic sphygmo-
manometer (BP98A; Softron, Tokyo, Japan) at the tail artery
whereas the animals were restrained.
LPO measurement
The level of TBARS, representing the extent of LPO, was measured
in tissue homogenates using the LPO test (Wako Pure Chemical), as
described previously.43
Insulin tolerance test
After 6-h fast, insulin (3 mU/g body weight) was injected
intraperitoneally into KKAy mice.22 Blood samples were obtained
at the indicated time intervals. Insulin sensitivity was estimated by
percentage changes in plasma glucose concentrations.
RNA extraction and quantitative reverse transcriptase-
polymerase chain reaction
Isolated total RNA was subjected to cDNA synthesis using
ThermoScript reverse transcriptase-polymerase chain reaction
System (Invitrogen, San Diego, CA, USA). Real-time polymerase
chain reaction was performed on an ABI PRISM 7700 using the
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SYBR GREEN polymerase chain reaction Master Mix (Applied
Biosystems, Warrington, UK). The sequences of primers were
designed for cyclophilin, adiponectin, TNF-a, PAI-1, MCP-1,
gp91phox, p22phox, p67phox, p47phox, p40phox, Cu, Zn-superoxide
dismutases, catalase,43 AT1a receptor,61 and SAA3,40 as reported
previously. The polymerase chain reaction primers for PU.1 and
36B4 were as follows; PU.1 50-CCGCACACCATGTCCACAAC-30
(forward), 50-GGACGTGCATCTGTTCCAGC-30 (reverse), and 36B4
50-AAGCGCGTCCTGGCATTGTCT-30 (forward) 50-CCGCAGGGG
CAGCAGTGGT-30 (reverse).
Statistical analysis
Data were expressed as mean7s.e.m. of n separate experi-
ments. Differences between groups were examined for statistical
significance using Student’s t-test or analysis of variance followed
by Fisher’s protected least significant test for comparisons
between two groups or among multiple groups, respectively.
A P-value less than 0.05 denoted the presence a statistically
significant difference.
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